Clinical Trial Update: Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update reporting results for melphalan, lenalidomide, and dexamethasone in AL amyloidosis (primary systemic amyloidosis), with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Melphalan (Melphalan)

Snippet

Sponsor: Boston Medical Center | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2017-02-20